Evidence map›Paper›PMID 41960338›Full record

ArticleResearch square2026

Structural and genetic analysis of neutralizing antibodies reveals mechanisms of GII.4 norovirus antigenic evolution.

Gabriel Parra, Kelsey Pilewski, Anisa Ghosh, Kentaro Tohma, Lauren Ford-Siltz, Adrian Hernandez, Monica Pajuelo, Michael Landivar, Rebecca DuBois

Abstract readPreprint
In one paragraph

Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Gabriel ParraFDA.ORCID 0000-0002-1102-4740
Kelsey PilewskiFDA.
Anisa GhoshUniversity of California Santa Cruz.
Kentaro TohmaFDA.
Lauren Ford-SiltzFDA.
Adrian HernandezFDA.
Monica PajueloUniversidad Peruana Cayetano Heredia.
Michael LandivarFDA.
Rebecca DuBoisUniversity of California, Santa Cruz.ORCID 0000-0003-4185-5673

Funding

A postdoctoral training program for impactful careers in stem cell biologyT32HD108079 · NICHD · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI Bin Chen, CAMILLA FORSBERG · 2022 to 2026
$1.1M
Structural mapping of an immunodominant antigenic site on the norovirus capsidR21AI180523 · NIAID · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI DUBOIS, REBECCA MICHELLE · 2024 to 2025
$430k
An Octet Bio-layer Interferometer for Macromolecular Interaction Studies at UCSCS10OD027012 · OD · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI RUBIN, SETH MICHAEL · 2019 to 2019
$370k
NIAID NIH HHS R21 AI180523NICHD NIH HHS T32 HD108079NIH HHS S10 OD027012
6 · The paper itself

Abstract

Noroviruses are a leading cause of acute gastroenteritis worldwide, yet no licensed vaccines or antivirals are available. A major barrier to broadly protective vaccine development is the extensive genetic and antigenic diversity of these viruses, leading to immune escape. However, the structural mechanisms underlying this immune escape remain incompletely defined. Here, we analyze a panel of monoclonal antibodies generated against a pandemic GII.4 variant to define the molecular determinants of neutralizing immunity. Guided by immunogenetic features and cross-reactivity patterns spanning four decades of viral evolution, we resolved the atomic structures of two neutralizing antibodies targeting the principal immunodominant antigenic sites, A and G. We show that the spatial positioning of antigenic site G shapes neutralizing responses and that coordinated substitutions within these epitopes drove the rapid antigenic transitions observed between 2004 and 2012.Together, these findings establish a structural framework for GII.4 antigenic evolution and inform rational vaccine design.

Indexed as

Antigenic evolutionEpitope mappingNorovirusViral evolution

Identifiers

PMID41960338
PMCPMC13060508

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.